Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Carcinoma × avelumab × Clear all

Phase

Status

Unknown 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 10 Neoplasms 9 Carcinoma, Transitional Cell 7 Neoplasm Metastasis 6 Colorectal Neoplasms 6 Urinary Bladder Neoplasms 5 Ovarian Neoplasms 5 Carcinoma, Renal Cell 4 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Glioblastoma 3 Carcinoma, Neuroendocrine 3 Stomach Neoplasms 2 Neuroendocrine Tumors 2 Kidney Neoplasms 2 Kidney Diseases 2 Glioma 2 Fallopian Tube Neoplasms 2 Carcinoma, Merkel Cell 2 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Urologic Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Testicular Neoplasms 1 Testicular Diseases 1 Sezary Syndrome 1 Sarcoma 1 Rectal Neoplasms 1

Interventions

Carboplatin 24 Paclitaxel 21 Gemcitabine 17 Cisplatin 16 pembrolizumab 12 Everolimus 8 Docetaxel 8 Radiotherapy, Intensity-Modulated 7 Pemetrexed 7 Fluorouracil 7 130-nm albumin-bound paclitaxel 7 Radiotherapy 6 Nivolumab 6 Cetuximab 6 Panitumumab 5 Cyclophosphamide 5 Bevacizumab 5 Axitinib 5 trebananib 4 lenvatinib 4 Sunitinib 4 Sorafenib 4 Irinotecan 4 Gefitinib 4 volociximab 3 reolysin 3 padeliporfin 3 epothilone B 3 durvalumab 3 Octreotide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03268057 2022-05-02

CLASSICAL-Lung

Vaccinex Inc.

Phase 1/2 Completed

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡